Ophthalmic drugs are the type of drugs which are used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders. According to the American Academy of Ophthalmology, 11.3 million people in the U.S. suffer from age-related macular degeneration (AMD), while approximately 10% of them are inflicted with wet AMD. Such trends in ophthalmic disorders across the globe contribute to the growth of the market.
Ophthalmic Drugs Market Segments Size & Growth:
Ophthalmic Drugs market size is projected to reach approximately $55 billion by the end of 2024 with a CAGR of close to 6.6% from $30.25 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Availability of new drugs and devices, the Huge demographic shift towards the emerging markets and Increase in the cataract population and so on. However, Increasing healthcare costs and an Economic slowdown in developed markets are thereby
Ophthalmic Drugs Market Segments Share:
Ophthalmic Drugs Market is categorised into drugs which comprise of Ophthalmic swelling, Mydriasis drugs, Ophthalmic inflammation drugs, Anti-glaucoma drugs and so on. Among the Drugs, Ophthalmic Infection Drugs market segment dominated the Ophthalmic Drugs market in 2018 with about XX% share. By Geography, North America is expected to dominate the Ophthalmic Drugs market, and the growth in the North America economies is mainly attributed because of higher uptake of advanced novel products and techniques, and the high cost of therapies among all regions. The market in North America is expected to become worth US$13.78 billion by 2024.
Ophthalmic Drugs Market Trends:
Ophthalmic Drugs Market Research Report:
Starting from $2700
Starting from $2700
Starting from $2700
Keep up-to-date with our weekly newsletter, Media Pulse.